Moderna raised its 2026 revenue growth forecast to 15% to 25%, up from previous guidance of up to 10%. CEO Stéphane Bancel said newer vaccines are gaining traction. The company swung to a profit as momentum for its cancer vaccine builds, and its stock jumped after the outlook increase.
Reporting from 3 identified publishers across this event arc.
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Page 69 of 21741
Same format. Every time.
Continue reading — sign in or create a free account with
